Agrimonolide, a molecule found in a traditional Chinese herb, eased liver damage, scarring, and inflammation in a mouse model of…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
BILIARY ATRESIA
NewsLiver Foundation honors family who turned diagnosis into giving
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver…
CHOLESTASIS
NewsPFIC Awareness Day means… spotlighting the rare liver disease
Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event…
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people…
CHOLANGITIS
NewsPBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with…
FATTY LIVER DISEASE
NewsFDA weighs noninvasive biopsy alternative in MASH clinical trials
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies…
BILIARY ATRESIA
NewsVirtual 5K expands annual run into national biliary atresia fundraiser
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness…
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against…
Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also…
HEPATITIS
NewsDosing begins in Phase 2 trial of ALG-000184 for hepatitis B
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184…